HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Attorney: FTC Put Industry “On Notice” With Nivea Case

This article was originally published in The Rose Sheet

Executive Summary

When the Federal Trade Commission seized upon Beiersdorf’s 2011 claims that Nivea My Silhouette! skin cream could substantially reduce consumers’ body size, it served as a reminder that the commission keeps an eye on personal-care claims, especially when they veer into the weight loss arena, according to attorney Richard Jacobson.

You may also be interested in...



FTC Fines L’Occitane For “Slimming” Claims, Calls For Media “Gut Check”

FTC settles with L’Occitane and three marketers of weight-loss products and launches its “gut check” voluntary media partnership program to help prevent bogus claims. Settlements with the four marketers totaled $33 million.

FTC/Beiersdorf Weight-Loss Cream Settlement Sends Message To Industry

The Federal Trade Commission’s recent settlement with Beiersdorf, which prohibits the firm from claiming that any product applied to skin causes substantial weight or fat loss, sends an “important message” to the cosmetics industry, an FTC rep said.

BORBA Enters Mass With Aspirations To Be "Synonymous With Innovation"

California-based “beautyceutical” marketer BORBA plans to broaden its customer base with the national debut of a new line exclusively at Walgreens, representing the brand’s first foray into the mass-market channel.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel